EVX-04 / Evaxion - LARVOL DELTA

PRECLINICAL CHARACTERIZATION OF EVX-04, AN AI-DESIGNED OFF-THE-SHELF CANCER VACCINE TARGETING ENDOGENOUS RETROVIRAL ANTIGENS IN ACUTE MYELOID LEUKEMIA (EHA 2026) - "Summary/Conclusion EVX-04 represents a promising therapeutic approach targeting ERV antigens in AML acting by inducing functional antigen-specific T cells with cytotoxic potential. Based on encouraging preclinical results, a first-in-human study combining EVX-04 with azacytidine and venetoclax is in planning."

First-in-human • IO biomarker • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • IFNG

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress (StockTitan.net) - "Evaxion will present new preclinical data on its off-the-shelf AML vaccine EVX-04 at the EHA 2026 Congress in Stockholm on June 13, 2026. The functional characterization data mark a step towards clinical testing, with a clinical trial application planned for the second half of 2026."

New trial • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting (GlobeNewswire) - "EVX-04 induces targeted immune responses and prevents tumor growth in preclinical models EVX-04 is an off-the-shelf therapeutic cancer vaccine developed for acute myeloid leukemia....The new data confirms that all 16 ERV fragments included in EVX-04 elicit a specific immune response and that EVX-04 prevents tumor growth in preclinical tumor models."

Preclinical • Acute Myelogenous Leukemia